Samlyn Capital LLC Sells 228,380 Shares of Insmed Incorporated (NASDAQ:INSM)

Samlyn Capital LLC lessened its holdings in Insmed Incorporated (NASDAQ:INSM) by 38.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 359,254 shares of the biopharmaceutical company’s stock after selling 228,380 shares during the period. Samlyn Capital LLC owned 0.24% of Insmed worth $24,070,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in Insmed by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 14,509,235 shares of the biopharmaceutical company’s stock valued at $393,636,000 after acquiring an additional 383,714 shares during the period. Principal Financial Group Inc. grew its holdings in Insmed by 15.2% in the 2nd quarter. Principal Financial Group Inc. now owns 1,657,760 shares of the biopharmaceutical company’s stock valued at $111,069,000 after buying an additional 218,480 shares in the last quarter. Capital International Investors acquired a new position in Insmed in the 1st quarter valued at $43,973,000. Norges Bank acquired a new position in Insmed in the 4th quarter valued at $45,029,000. Finally, Hood River Capital Management LLC grew its holdings in Insmed by 36.7% in the 2nd quarter. Hood River Capital Management LLC now owns 1,315,392 shares of the biopharmaceutical company’s stock valued at $88,131,000 after buying an additional 352,891 shares in the last quarter.

Insider Buying and Selling at Insmed

In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of the stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $74.92, for a total value of $1,006,625.12. Following the completion of the transaction, the insider now directly owns 106,134 shares in the company, valued at $7,951,559.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Martina M.D. Flammer sold 13,436 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the transaction, the insider now directly owns 106,134 shares in the company, valued at $7,951,559.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total value of $2,686,612.50. Following the transaction, the insider now owns 100,100 shares of the company’s stock, valued at $7,157,150. The disclosure for this sale can be found here. Over the last three months, insiders sold 78,882 shares of company stock worth $5,765,446. 4.60% of the stock is currently owned by insiders.

Insmed Stock Performance

NASDAQ:INSM opened at $71.82 on Tuesday. The company has a quick ratio of 2.53, a current ratio of 2.71 and a debt-to-equity ratio of 25.05. The firm has a market capitalization of $10.67 billion, a PE ratio of -13.73 and a beta of 1.11. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $80.53. The stock’s 50-day simple moving average is $74.57 and its 200 day simple moving average is $52.52.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The business had revenue of $90.34 million during the quarter, compared to analysts’ expectations of $87.95 million. The company’s revenue was up 17.0% on a year-over-year basis. During the same period in the previous year, the company earned ($1.78) EPS. On average, analysts anticipate that Insmed Incorporated will post -5.42 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

INSM has been the topic of a number of research reports. Guggenheim upped their price objective on Insmed from $70.00 to $95.00 and gave the company a “buy” rating in a report on Tuesday, July 9th. Bank of America reaffirmed a “buy” rating and issued a $83.00 price objective on shares of Insmed in a report on Friday, July 5th. Evercore ISI increased their target price on Insmed from $42.00 to $75.00 and gave the stock an “outperform” rating in a report on Friday, June 21st. HC Wainwright reissued a “buy” rating and set a $90.00 target price on shares of Insmed in a report on Thursday, August 29th. Finally, TD Cowen increased their target price on Insmed from $75.00 to $98.00 and gave the stock a “buy” rating in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Insmed has a consensus rating of “Moderate Buy” and a consensus price target of $81.40.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.